nct_id: NCT05497102
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2022-08-11'
study_start_date: '2021-11-08'
study_completion_date: null
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Drug: Lenalidomide maintenance'
long_title: Phase II, Single-arm Trial of Carfilzomib, Lenalidomide, and Dexamethasone
  Re-induction Followed by the 2nd ASCT in Multiple Myeloma Patients Relapsed After
  the 1st ASCT
last_updated: '2022-08-12'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE2
principal_investigator: Kihyun Kim, M.D., Ph.D
principal_investigator_institution: Samsung Medical Center
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 58
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- 'Inclusion Criteria:'
- 1. Age 20\~70
- 2. Progressive disease after 1st ASCT
- 3. Duration of response after 1st ASCT \> 12 months
- 4. Measurable disease (+)
- "* Serum M-protein \u2265 1 g/dL"
- "* Urine M-protein \u2265 200 mg/24 hr"
- "* Serum Free Light Chain(FLC) assay: involved FLC level \u226510 mg/dL (serum Free\
  \ Light Chain ratio is abnormal)"
- 5. Adequate organ function for induction \& ASCT
- "* Absolute Neutrophil Count (ANC) \u2265 1.0 x 109/L"
- "* Platelets \u2265 50 x 109/L (\u2265 30 x 109/L if myeloma involvement is \\>\
  \ 50% in the bone marrow)"
- "* Hemoglobin \u2265 8.0 g/dL"
- "* Creatinine clearance \u2265 30 mL/minute"
- "* Serum Bilirubin \u2264 1.5 x upper limit of normal"
- "* Aspartate aminotransferase(AST) and Alanine aminotransferase(ALT) \u2264 3 x\
  \ upper limit of normal"
- 6. Eastern Cooperative Oncology Group performance scale 0\~2
- 7. Survival expectancy \> 3 months
- 8. Adequately controlled hepatitis B(HBV) \& hepatitis C(HCV)
- 9. Written informed consent
- 10. Optimal contraceptions
- 'Exclude - Exclusion Criteria:'
- Exclude - 1. Prior refractoriness or intolerance to carfilzomib
- Exclude - 2. Prior refractoriness or intolerance to lenalidomide/dexamethasone
- Exclude - 3. Any treatment after progressive disease after 1st ASCT. High-dose dexamethasone
  or palliative radiation is permitted.
- Exclude - 4. Waldenstroem's macroglobulinemia, POEMS syndrome, or plasma cell leukemia
- Exclude - 5. Pregnant or nursing lactating women
- Exclude - 6. Myocardial infarct within 6 months, heart failure of New York Heart
  Association(NYHA) Class III\~IV, uncontrolled ventricular arrhythmia, severe coronary
  arterial obstructive disease
- Exclude - 7. Uncontrolled hypertension (Defined as an average systolic blood pressure
  \>= 160 mmHg or diastolic \>= 100 mmHg) or diabetes
- Exclude - 8. Grade 3\~4 neuropathy
- Exclude - 9. HIV infection
- Exclude - 10. Severe or uncontrolled medical conditions, laboratory abnormalities,
  or psychiatric disorders that may preclude the participation of the study by the
  physician's discretion
- Exclude - 11. Contraindication to any of the required concomitant drugs or supportive
  treatments, including hypersensitivity to all anticoagulation and antiplatelet options,
  antiviral drugs, or intolerance to hydration due to preexisting pulmonary or cardiac
  impairment
- Exclude - 12. Diagnosis of other malignant disease other than myeloma within 5 year.
  Exceptions are properly treated non-melanomatous skin cancers, cervical intraepithelial
  neoplasia, prostate cancer that do not require treatment, or properly excised well-differentiated
  thyroid cancers
short_title: Carfilzomib, Lenalidomide, and Dexamethasone Re-induction Followed by
  the 2nd ASCT in Multiple Myeloma Patients Relapsed After the 1st ASCT
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: Samsung Medical Center
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: The purpose of this study is to evaluate the efficacy and safety of salvage
  treatment with carfilzomib/lenalidomide/dexamethasone (KRD) followed by 2nd autologous
  stem cell transplantation (ASCT) and lenalidomide maintenance in patients with relapsed
  myeloma after 1st ASCT.
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: Single arm of Lenalidomide maintenance
      arm_internal_id: 0
      arm_description: '\[KRd #1\~6, Every 4 weeks\] D1, 2, 8, 9, 15,16 Carfilzomib
        20mg/m2 + 5% dextrose in water 50 mL over 10 mins (From Cycle1Day8 27mg/m2)
        D1 - 21 Lenalidomide 25mg P.O. D1, 8, 15, 22 Dexamethasone 40mg IV or PO


        \[Autologous stem cell transplantation phase\]


        \[Lenalidomide maintenance phase, Every 4 weeks\] D1-28 Lenalidomide 10 mg'
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Lenalidomide maintenance'
        level_internal_id: 0
        level_suspended: N
    match:
    - clinical:
        age_numerical: '>=20'
        disease_status:
        - Refractory
        oncotree_primary_diagnosis: Lymphoid Neoplasm
